中國同輻:2023年經濟效益持續增長 全年營收66.35億元
中國同輻(1763.HK)公吿,2023年公司持續加大市場開拓力度,經濟效益實現持續增長。全年實現營業收入人民幣66.35億元,同比增長7.82%;淨利潤人民幣7.76億元,同比增長2.77%;歸母淨利潤人民幣3.71億元。每股盈利1.16人民幣元。公司經營藥品、放射源產品、輻照、放射治療設備及相關服務,以及其他業務五個業務分部。藥品業務存量產業發展如火如荼,通過舉行學術會議等方式穩步擴大行業影響力;放射源產品成功服務神舟十五號載人飛船,產品持續保持高市場佔有率;輻照業務持續創新合作模式,新產品銷售收入再創新高,超0.28 億元。高端放療設備國產化加速推進,中國高端醫療領域的首款國產螺旋斷層放療產品成功獲批;國際業務逐步深化全球佈局,多項業務取得突破;截至2023年12月31日,公司擁有有效專利945項,科技實力不斷增強。公司表示未來將充分發揮核醫學在神經退行性疾病、心腦血管病、惡性腫瘤等重大疾病診斷及治療方面的獨特優勢,通過提供優質的產品、服務及整體解決方案,更好地守護人民生命健康,助力「健康中國」建設。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.